Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema

Basit Öğe Kaydı
dc.contributor.authorGuler, Emre
dc.contributor.authorTotan, Yuksel
dc.contributor.authorGuragac, Fatma Betul
dc.date.accessioned2025-10-24T18:09:45Z
dc.date.available2025-10-24T18:09:45Z
dc.date.issued2017
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractObjective: To evaluate anatomical and functional outcomes of intraviteal bevacizumab (IVB) in patients with chronic diabetic macular edema (DME), and the effectivity and safety of dexamethasone implant in those unresponsive to regular IVB treatment. Methods: Thirty-five eyes of 35 patients (16 male and 19 female) with chronic DME (central foveal thickness (CFT) >275m, duration >6 months) received three injections of 2.5mg IVB with six-week intervals. At 18 weeks, dexamethasone implant was applied to patients unresponsive to IVB. Main outcomes were the change in best corrected visual acuity (BCVA), CFT and ocular and systemic adverse effects for both drugs. The patients responsive to IVB were followed up for 36 weeks and those patients receiving dexamethasone implant were followed up for 24 weeks postoperatively. Results: At 18 weeks, the mean BCVA (0.68 +/- 0.40 logMAR, p=0.45) and CFT (453 +/- 169m, p=0.58) did not show any significant change compared to baseline (0.74 +/- 0.42 logMAR and 521 +/- 151m, respectively). In 20 patients (%57.1) responsive to IVB, the CFT was significantly improved from 12 to 36 weeks with the mean value of 295 +/- 42 (p=0.01). However, no significant difference was observed for BCVA during this period (p=0.17). Dexamethasone was implanted in 15 eyes (42.8%) unresponsive to IVB at 18 weeks. Statistically significant improvements were observed in BCVA (at postoperative 4 and 12 weeks) and CFT (at postoperative 4, 12 and 24 weeks). In addition, both parameters significantly worsened at 24 weeks compared to 12 weeks (p<0.001 and p=0.01, respectively). Conclusions: Patients with chronic DME should be followed in accordance with a fixed treatment protocol combining anti-VEGF and steroid treatments.
dc.identifier.doi10.3109/15569527.2015.1127254
dc.identifier.endpage184
dc.identifier.issn1556-9527
dc.identifier.issn1556-9535
dc.identifier.issue2
dc.identifier.pmid28366074
dc.identifier.scopus2-s2.0-85014576165
dc.identifier.scopusqualityQ3
dc.identifier.startpage180
dc.identifier.urihttps://doi.org/10.3109/15569527.2015.1127254
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3812
dc.identifier.volume36
dc.identifier.wosWOS:000399501400014
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofCutaneous And Ocular Toxicology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectAnti-VEGF therapy; bevacizumab; dexamethasone implant; diabetic macular edema; inflammation
dc.titleIntravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu